Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.59 |
| ▸ | NPY1R | P25929 | 11/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.59 |
| ▸ | NPY2R | P49146 | 7/20 | 0.59 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241711 | 0.90 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL241712 | 0.90 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL29947137 | 0.86 | NPY4R (0.70) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29947151 | 0.86 | NPY4R (0.70) | NPY4RNPY1RNPY5RNPY2R | |
| Acetic Acid SCHEMBL9189505 | 0.86 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL18758146 | 0.86 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2R | |
| Acetic Acid SCHEMBL9189488 | 0.86 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13707502 | 0.86 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30958046 | 0.86 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3138301 | 0.86 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107255-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107255-A1 | APELIN POLYPEPTIDES | APLNR, FABP3, AP3B1 | NPY4R 847/4885NPY1R 781/4885NPY5R 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.